Compass Therapeutics (CMPX) EBITDA (2018 - 2026)
Compass Therapeutics recorded quarterly EBITDA of -$18.8 million in Q1 2026, down 19.39% quarter-over-quarter from -$15.7 million in Q4 2025, and down 12.63% year-over-year from -$21.5 million in Q1 2025.
Compass Therapeutics' EBITDA history runs 9 years deep, the most recent figure standing at -$18.8 million for Q1 2026.
- In Q1 2026, EBITDA fell 12.63% year-over-year to -$18.8 million; the TTM figure through Mar 2026 stood at -$68.5 million (down 24.71% YoY), while the FY2025 annual figure was -$66.4 million, down 34.99% from the prior year.
- EBITDA came in at -$18.8 million for Q1 2026 at Compass Therapeutics, down from -$15.7 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$7.2 million in Q1 2022 to a low of -$19.9 million in Q2 2025.
- A 5-year average of -$12.7 million and a median of -$12.1 million in 2022 frame the typical range for EBITDA.
- Across the five-year window, EBITDA plunged 102.58% in 2022 and gained 18.32% in 2023, its largest moves.
- Compass Therapeutics' EBITDA stood at -$11.3 million in 2022, then declined by 15.04% to -$12.9 million in 2023, then fell by 18.23% to -$15.3 million in 2024, then decreased by 2.62% to -$15.7 million in 2025, then dropped by 19.39% to -$18.8 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$18.8 million, -$15.7 million, and -$14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | -18.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.76 Mn |
| Dec 31, 2025 | -15.71 Mn |
| Sep 30, 2025 | -14.19 Mn |
| Jun 30, 2025 | -19.86 Mn |
| Mar 31, 2025 | -16.65 Mn |
| Dec 31, 2024 | -15.31 Mn |
| Sep 30, 2024 | -9.90 Mn |
| Jun 30, 2024 | -13.08 Mn |
| Mar 31, 2024 | -10.91 Mn |
| Dec 31, 2023 | -12.95 Mn |
| Sep 30, 2023 | -9.89 Mn |
| Jun 30, 2023 | -11.64 Mn |
| Mar 31, 2023 | -7.68 Mn |
| Dec 31, 2022 | -11.26 Mn |
| Sep 30, 2022 | -12.10 Mn |
| Jun 30, 2022 | -9.01 Mn |
| Mar 31, 2022 | -7.16 Mn |
| Dec 31, 2021 | -12.98 Mn |
| Sep 30, 2021 | -5.98 Mn |
| Mar 31, 2021 | -7.34 Mn |
| Sep 30, 2020 | -8.96 Mn |
| Jun 30, 2020 | -5.07 Mn |
| Mar 31, 2020 | -5.83 Mn |
| Dec 31, 2019 | -10,238.00 |
| Sep 30, 2019 | -8.38 Mn |
| Jun 30, 2019 | -8.67 Mn |
| Dec 31, 2018 | -9,267.00 |
| Sep 30, 2018 | -7,785.00 |
| Jun 30, 2018 | -7,894.00 |